Immune checkpoint inhibitors versus second line chemotherapy for patients with lung cancer refractory to first line chemotherapy

C. Lefebvre; E. Martin; L. E. L. Hendriks; R. Veillon; F. Puisset; L. Mezquita; R. Ferrara; M. Sabatier; T. Filleron; A-M C. Dingemans; B. Besse; C. Raherisson; J. Mazieres

doi:10.1016/j.resmer.2020.100788

Immune checkpoint inhibitors versus second line chemotherapy for patients with lung cancer refractory to first line chemotherapy

C. Lefebvre, E. Martin, L. E. L. Hendriks, R. Veillon, F. Puisset, L. Mezquita, R. Ferrara, M. Sabatier, T. Filleron, A-M C. Dingemans, B. Besse, C. Raherisson, J. Mazieres^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Article number	100788
Number of pages	7
Journal	Respiratory medicine and research
Volume	78
DOIs	https://doi.org/10.1016/j.resmer.2020.100788
Publication status	Published - Nov 2020

Keywords

DOCETAXEL
NIVOLUMAB
PHASE-3

Access to Document

10.1016/j.resmer.2020.100788

Embargoed Document

Full Text
Final published version, 908 KB
Licence: Taverne
Embargo ends: 1/05/21
Request copy

Cite this

Lefebvre, C., Martin, E., Hendriks, L. E. L., Veillon, R., Puisset, F., Mezquita, L., Ferrara, R., Sabatier, M., Filleron, T., Dingemans, A-M. C., Besse, B., Raherisson, C., & Mazieres, J. (2020). Immune checkpoint inhibitors versus second line chemotherapy for patients with lung cancer refractory to first line chemotherapy. Respiratory medicine and research, 78, [100788]. https://doi.org/10.1016/j.resmer.2020.100788

Lefebvre, C. ; Martin, E. ; Hendriks, L. E. L. ; Veillon, R. ; Puisset, F. ; Mezquita, L. ; Ferrara, R. ; Sabatier, M. ; Filleron, T. ; Dingemans, A-M C. ; Besse, B. ; Raherisson, C. ; Mazieres, J. / Immune checkpoint inhibitors versus second line chemotherapy for patients with lung cancer refractory to first line chemotherapy. In: Respiratory medicine and research. 2020 ; Vol. 78.

@article{b389e4442d7f441295f5257c11734e38,

title = "Immune checkpoint inhibitors versus second line chemotherapy for patients with lung cancer refractory to first line chemotherapy",

keywords = "DOCETAXEL, NIVOLUMAB, PHASE-3",

author = "C. Lefebvre and E. Martin and Hendriks, {L. E. L.} and R. Veillon and F. Puisset and L. Mezquita and R. Ferrara and M. Sabatier and T. Filleron and Dingemans, {A-M C.} and B. Besse and C. Raherisson and J. Mazieres",

year = "2020",

month = nov,

doi = "10.1016/j.resmer.2020.100788",

language = "English",

volume = "78",

journal = "Respiratory medicine and research",

issn = "2590-0412",

publisher = "Elsevier",

}

Lefebvre, C, Martin, E, Hendriks, LEL, Veillon, R, Puisset, F, Mezquita, L, Ferrara, R, Sabatier, M, Filleron, T, Dingemans, A-MC, Besse, B, Raherisson, C & Mazieres, J 2020, 'Immune checkpoint inhibitors versus second line chemotherapy for patients with lung cancer refractory to first line chemotherapy', Respiratory medicine and research, vol. 78, 100788. https://doi.org/10.1016/j.resmer.2020.100788

Immune checkpoint inhibitors versus second line chemotherapy for patients with lung cancer refractory to first line chemotherapy. / Lefebvre, C.; Martin, E.; Hendriks, L. E. L.; Veillon, R.; Puisset, F.; Mezquita, L.; Ferrara, R.; Sabatier, M.; Filleron, T.; Dingemans, A-M C.; Besse, B.; Raherisson, C.; Mazieres, J.

In: Respiratory medicine and research, Vol. 78, 100788, 11.2020.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Immune checkpoint inhibitors versus second line chemotherapy for patients with lung cancer refractory to first line chemotherapy

AU - Lefebvre, C.

AU - Martin, E.

AU - Hendriks, L. E. L.

AU - Veillon, R.

AU - Puisset, F.

AU - Mezquita, L.

AU - Ferrara, R.

AU - Sabatier, M.

AU - Filleron, T.

AU - Dingemans, A-M C.

AU - Besse, B.

AU - Raherisson, C.

AU - Mazieres, J.

PY - 2020/11

Y1 - 2020/11

KW - DOCETAXEL

KW - NIVOLUMAB

KW - PHASE-3

U2 - 10.1016/j.resmer.2020.100788

DO - 10.1016/j.resmer.2020.100788

M3 - Article

C2 - 32980653

VL - 78

JO - Respiratory medicine and research

JF - Respiratory medicine and research

SN - 2590-0412

M1 - 100788

ER -